J Drugs Dermatol. 2023 Aug 1;22(8):840-843. doi: 10.36849/jdd.6593.
The early phase of the COVID-19 pandemic prompted a repurposing of antiviral and immunomodulatory drugs as investigational therapeutics, including hydroxychloroquine and chloroquine. While antimalarials have been well-refuted as a treatment for COVID-19, data on these drugs' role in preventing SARS-CoV-2 infection as pre-exposure prophylaxis is more limited. We investigated the efficacy of antimalarial drugs as pre-exposure SARS-CoV-2 prophylaxis in a US tertiary-care center. We identified all adult patients exposed to antimalarials with active prescriptions from July 1, 2019 to February 29, 2020 and exact-matched antimalarial-treated study patients with controls on age, sex, race, and Charleston Comorbidity Index. We used multivariable logistic regression to calculate the odds ratio (OR) of COVID-19 diagnosis by antimalarial exposure, adjusting for demographics, comorbidities, local infection rates, and specific conditions identified in early studies as risk factors for COVID-19. There were 3,074 patients with antimalarial prescriptions and 58,955 matched controls. Hydroxychloroquine represented 98.8% of antimalarial prescriptions. There were 51 (1.7%) infections among antimalarial-exposed and 973 (1.6%) among controls. No protective effect for SARS-CoV-2 infection was demonstrated among antimalarial-exposed patients in the multivariate model (OR=1.06, 95% CI 0.80-1.40, P=0.70). These findings corroborate prior work demonstrating that hydroxychloroquine and related antimalarials do not have a role in protection against SARS-CoV-2.Klebanov N, Pahalyants V, Said JT, et al. Antimalarials are not effective as pre-exposure prophylaxis for COVID-19: a retrospective matched control study. J Drugs Dermatol. 2023;22(8):840-843. doi:10.36849/JDD.6593.
抗疟药物作为 COVID-19 的治疗药物在早期阶段被重新利用，包括羟氯喹和氯喹。虽然抗疟药物已被充分证明不能治疗 COVID-19，但关于这些药物在预防 SARS-CoV-2 感染方面作为暴露前预防的作用的数据则更为有限。我们在美国一家三级保健中心研究了抗疟药物作为 SARS-CoV-2 暴露前预防的疗效。我们确定了所有在 2019 年 7 月 1 日至 2020 年 2 月 29 日期间有抗疟药物活性处方的成年患者，并按年龄、性别、种族和Charleston 合并症指数与抗疟药物治疗的研究患者进行了精确匹配。我们使用多变量逻辑回归计算了抗疟药物暴露与 COVID-19 诊断的比值比（OR），并调整了人口统计学、合并症、当地感染率以及早期研究中确定的与 COVID-19 相关的特定危险因素。共有 3074 例有抗疟药物处方的患者和 58955 例匹配的对照。羟氯喹占抗疟药物处方的 98.8%。抗疟药物暴露组有 51 例（1.7%）感染，对照组有 973 例（1.6%）感染。在多变量模型中，抗疟药物暴露患者未显示出对 SARS-CoV-2 感染的保护作用（OR=1.06，95%CI 0.80-1.40，P=0.70）。这些发现与先前的工作一致，表明羟氯喹和相关抗疟药物在预防 SARS-CoV-2 方面没有作用。
Klebanov N, Pahalyants V, Said JT, et al. Antimalarials are not effective as pre-exposure prophylaxis for COVID-19: a retrospective matched control study. J Drugs Dermatol. 2023;22(8):840-843. doi:10.36849/JDD.6593.
